Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

(2016) Fred Poordad et al.   HEPATOLOGY

Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

(2015) Graham R. Foster et al.   GASTROENTEROLOGY

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

(2015) Eric Lawitz et al.   HEPATOLOGY

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

(2015) David R. Nelson et al.   HEPATOLOGY

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

(2015)   HEPATOLOGY

EASL Recommendations on Treatment of Hepatitis C 2015

(2015)   JOURNAL OF HEPATOLOGY

Global distribution and prevalence of hepatitis C virus genotypes

(2014) Jane P. Messina et al.   HEPATOLOGY

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

(2014) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients

(2013) A. H. Talal et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection

(2013) David Alan Herbst et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

(2013) Eric Lawitz et al.   LANCET INFECTIOUS DISEASES

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

(2013) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

(2013) Edward J. Gane et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

(2013) Eric Lawitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

(2011) G. Nkontchou et al.   JOURNAL OF VIRAL HEPATITIS

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C

(2009) Pierre-Yves Bochud et al.   JOURNAL OF HEPATOLOGY